<DOC>
	<DOC>NCT01057251</DOC>
	<brief_summary>The primary object of this study is to evaluate the efficacy and safety of 6 weeks of nebivolol monotherapy compared with placebo in patients with systolic stage 2 hypertension.</brief_summary>
	<brief_title>Nebivolol in Patients With Systolic Stage 2 Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Nebivolol</mesh_term>
	<criteria>male of female, 18 to 64 years of age at screening mean seated heart rate at least 60 bpm diagnosed systolic stage 2 hypertension unremarkable physical exam findings high risk due to secondary hypertension or former stage 3 hypertension by JNC6 concurrent conditions (reno, cardiovascular, obesity, thyroid, etc) currently taking medication that cannot be stopped during the course of the study participating other clinical trials member of the study center personnel documented drug abuse contra indication to beta blocker abnormal lab finding poor compliance other conditions judged by investigator that is not suitable for the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Nebivolol</keyword>
	<keyword>Bystolic TM</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Stage 2 Hypertension</keyword>
</DOC>